A Phase 3 interventional study of Rotavirus Vaccine, Live, Oral, Pentavalent and Comparator: Oral Poliovirus Vaccine (OPV) in Rotavirus Infections and Gastroenteritis, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 6 Weeks to 12 Weeks, including healthy volunteers. Per ClinicalTrials.gov, last updated 2015-04-01.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The study is being conducted to demonstrate that vaccine to prevent gastroenteritis due to rotavirus may be administered concomitantly with oral polio vaccine (OPV) without impairing the safety or immunogenicity of either vaccine.
104 studies on the registry are indexed under Rotavirus Infections; 3 are open to participants now.
This study's enrollment of 735 is above the median of 403 across 69 interventional studies indexed under Rotavirus Infections.
Browse Rotavirus Infections studies →Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 504 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RotaTeq and OPV concomitantly
Biological: Rotavirus Vaccine, Live, Oral, Pentavalent · Biological: Comparator: Oral Poliovirus Vaccine (OPV)
RotaTeq and OPV on staggered schedule
Biological: Rotavirus Vaccine, Live, Oral, Pentavalent · Biological: Comparator: Oral Poliovirus Vaccine (OPV) (staggered)
Three doses of rotavirus vaccine, live, oral, pentavalent. Dose 1 was given on Day 1, Dose 2 was given 56 to 84 days post Dose 1, and Dose 3 was given 56 to 84 days post Dose 2.
Three doses OPV. Dose 1 was given on Day 1, Dose 2 was given 56 to 84 days post Dose 1, and Dose 3 was given 56 to 84 days post Dose 2.
Three doses OPV. Dose 1 was given 14 to 28 days post Dose 1 of RotaTeq, Dose 2 was given 14 to 28 days post Dose 2 of RotaTeq, and Dose 3 was given 14 to 28 days post Dose 3 of RotaTeq.
Geometric Mean Titer(s) of Poliovirus Types 1, 2, and 3, Measured Approximately 42 Days Postdose 3
GMT of poliovirus type 1, 2, and 3, measured at postdose 3 in subjects receiving RotaTeq™ and OPV concomitantly compared to staggered.
Time frame: Approximately 42 days Postdose 3
GMT of Serum Anti-rotavirus Immunoglobulin A (IgA)
GMT of serum anti-rotavirus IgA measured at postdose 3 in subjects receiving RotaTeq™ and OPV concomitantly compared to staggered
Time frame: Approximately 42 days Postdose 3
Immunogenicity of RotaTeq™ as Measured by Serum Neutralizing Antibody [SNA] Responses to Rotavirus Serotypes G1, G2, G3, G4, and P1A When Administered With OPV Concomitantly or Staggered
Rotavirus SNA response to serotypes G1, G2, G3, G4, and P1A measured at postdose 3 in subjects receiving RotaTeq™ and OPV concomitantly compared to staggered.
Time frame: Approximately 42 days Postdose 3
Enrollment occurred at 9 study sites in Mexico, Costa Rica, Guatemala, and Brazil from 19-Oct-2005 (first subject in) to 06-Jan-2006 (last subject randomized).
| Milestone | RotaTeq and Oral Poliovirus (OPV) Concomitantly | RotaTeq and Oral Poliovirus (OPV) Staggered |
|---|---|---|
| Started | 372 | 363 |
| Completed | 356 | 346 |
| Not completed | 16 | 17 |
| Withdrew: Adverse event | 1 | 1 |
| Withdrew: Lost to follow-up | 1 | 2 |
| Withdrew: Protocol violation | 6 | 8 |
| Withdrew: Withdrawal by subject | 6 | 1 |
| Withdrew: Moved | 2 | 2 |
| Withdrew: Other | 0 | 3 |
GMT of poliovirus type 1, 2, and 3, measured at postdose 3 in subjects receiving RotaTeq™ and OPV concomitantly compared to staggered.
| Geometric Mean Titer (GMT) | RotaTeq and Oral Poliovirus (OPV) Concomitantly | RotaTeq and Oral Poliovirus (OPV) Staggered |
|---|---|---|
| Antibody Responses to Poliovirus Type 1 | 888.0 (752.8 to 1047) | 1139 (969.1 to 1340) |
| Antibody Responses to Poliovirus Type 2 | 814.9 (720.7 to 921.4) | 814.5 (707.4 to 937.9) |
| Antibody Responses to Poliovirus Type 3 | 233.6 (201.9 to 270.2) | 269.2 (230.6 to 314.2) |
GMT of serum anti-rotavirus IgA measured at postdose 3 in subjects receiving RotaTeq™ and OPV concomitantly compared to staggered
| GMT | RotaTeq and Oral Poliovirus (OPV) Concomitantly | RotaTeq and Oral Poliovirus (OPV) Staggered |
|---|---|---|
| GMT of Serum Anti-rotavirus Immunoglobulin A (IgA) | 154.9 (126.4 to 189.9) | 292.7 (248.6 to 344.6) |
Rotavirus SNA response to serotypes G1, G2, G3, G4, and P1A measured at postdose 3 in subjects receiving RotaTeq™ and OPV concomitantly compared to staggered.
| GMT | RotaTeq and Oral Poliovirus (OPV) Concomitantly | RotaTeq and Oral Poliovirus (OPV) Staggered |
|---|---|---|
| SNA responses to rotavirus serotypes G1 | 125.8 (106.7 to 148.2) | 182.6 (158.2 to 210.7) |
| SNA responses to rotavirus serotypes G2 | 27.1 (22.9 to 32.0) | 30.0 (25.9 to 34.8) |
| SNA responses to rotavirus serotypes G3 | 21.2 (18.4 to 24.32) | 22.5 (19.4 to 26.0) |
| SNA responses to rotavirus serotypes G4 | 58.5 (50.2 to 68.1) | 74.5 (64.3 to 86.3) |
| SNA responses to rotavirus serotypes P1A | 84.7 (71.97 to 99.8) | 131.4 (112.6 to 153.2) |
Collected over Subjects in this study were followed for all adverse experiences, for 14 days following each study vaccination.. Non-serious events are listed at a 1% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| RotaTeq and Oral Poliovirus (OPV) Concomitantly | — | 4/366 (1.1%) | 342/366 (93.4%) |
| RotaTeq and Oral Poliovirus (OPV) Staggered | — | 9/359 (2.5%) | 325/359 (90.5%) |
| Event | RotaTeq and Oral Poliovirus (OPV) Concomitantly | RotaTeq and Oral Poliovirus (OPV) Staggered |
|---|---|---|
| OverdoseInjury, poisoning and procedural complications | 0/366 | 4/359 |
| PneumoniaInfections and infestations | 0/366 | 2/359 |
| BronchiolitisInfections and infestations | 2/366 | 0/359 |
| IntussusceptionGastrointestinal disorders | 0/366 | 1/359 |
| PyrexiaGeneral disorders | 0/366 | 1/359 |
| PertussisInfections and infestations | 0/366 | 1/359 |
| Pleural effusionRespiratory, thoracic and mediastinal disorders | 0/366 | 1/359 |
| Meningitis pneumococcalInfections and infestations | 1/366 | 0/359 |
| Head injuryInjury, poisoning and procedural complications | 1/366 | 0/359 |
| Event | RotaTeq and Oral Poliovirus (OPV) Concomitantly | RotaTeq and Oral Poliovirus (OPV) Staggered |
|---|---|---|
| PyrexiaGeneral disorders | 203/366 | 202/359 |
| DiarrhoeaGastrointestinal disorders | 195/366 | 185/359 |
| VomitingGastrointestinal disorders | 123/366 | 121/359 |
| NasopharyngitisInfections and infestations | 85/366 | 86/359 |
| CoughRespiratory, thoracic and mediastinal disorders | 54/366 | 52/359 |
| InfluenzaInfections and infestations | 28/366 | 38/359 |
| Infantile colicGastrointestinal disorders | 34/366 | 37/359 |
| PharyngitisInfections and infestations | 32/366 | 37/359 |
| IrritabilityGeneral disorders | 24/366 | 33/359 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 23/366 | 18/359 |
| Age, Customized(participants) | RotaTeq and Oral Poliovirus (OPV) Concomitantly | RotaTeq and Oral Poliovirus (OPV) Staggered | Total |
|---|---|---|---|
| 5 Weeks of Age and Under | 8 | 1 | 9 |
| 6 to 12 Weeks of Age | 364 | 362 | 726 |
| Over 12 Weeks of Age | 0 | 0 | 0 |
| Sex: Female, Male(Participants) | RotaTeq and Oral Poliovirus (OPV) Concomitantly | RotaTeq and Oral Poliovirus (OPV) Staggered | Total |
|---|---|---|---|
| Female | 189 | 194 | 383 |
| Male | 183 | 169 | 352 |
| Race/Ethnicity, Customized(participants) | RotaTeq and Oral Poliovirus (OPV) Concomitantly | RotaTeq and Oral Poliovirus (OPV) Staggered | Total |
|---|---|---|---|
| Asian | 2 | 1 | 3 |
| Black | 10 | 7 | 17 |
| Hispanic American | 263 | 257 | 520 |
| Multi-Racial | 56 | 61 | 117 |
| White | 41 | 37 | 78 |
No study locations are listed for this record.
The record gives a start of Oct 2005, a primary completion of Jul 2006 and a completion of Jul 2006. It does not say whether these dates are actual or estimated.
Results were first posted in Sep 2010, 4 years 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Poliovirus Vaccine, Oral